Bausch Health Companies Inc. (BHC) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income $740.00M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$950.00M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income $619.00M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income $444.00M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | $740.00M | (m) | $2.85B | (m) | $77.00M* | $670.00M* | (m) | (m) | $907.00M | $88.00M |
| 2026-03-31 | Reported | (m) | -$950.00M | (m) | $2.52B | (m) | $109.00M | $230.00M | (m) | (m) | $861.00M | $77.00M |
| 2025-09-30 | Reported | (m) | $619.00M | (m) | $2.68B | (m) | $91.00M* | $405.00M* | (m) | (m) | $795.00M | $37.00M |
| 2025-06-30 | Reported | (m) | $444.00M | (m) | $2.53B | (m) | $99.00M* | $289.00M* | (m) | (m) | $894.00M | $12.00M |
| 2025-03-31 | Reported | (m) | $276.00M | (m) | $2.26B | (m) | $115.00M | $211.00M | (m) | (m) | $867.00M | $39.00M |
| 2024-09-30 | Reported | (m) | $318.00M | (m) | $2.51B | (m) | $71.00M* | $405.00M* | (m) | (m) | $850.00M | $71.00M |
| 2024-06-30 | Reported | (m) | $389.00M | (m) | $2.40B | (m) | $78.00M* | $380.00M* | (m) | (m) | $832.00M | $49.00M |
| 2024-03-31 | Reported | (m) | $281.00M | (m) | $2.15B | (m) | $82.00M | $211.00M | (m) | (m) | $794.00M | $8.00M |
| 2023-09-30 | Reported | (m) | $14.00M | (m) | $2.24B | (m) | $42.00M* | $282.00M* | (m) | (m) | $715.00M | $56.00M |
| 2023-06-30 | Reported | (m) | $412.00M | (m) | $2.17B | (m) | $28.00M* | $206.00M* | (m) | (m) | $711.00M | $52.00M |
| 2023-03-31 | Reported | (m) | $175.00M | (m) | $1.94B | (m) | $47.00M | $154.00M | (m) | (m) | $725.00M | $73.00M |
| 2022-09-30 | Reported | (m) | $244.00M | (m) | $2.05B | (m) | $54.00M* | -$1.26B* | (m) | (m) | $661.00M | $36.00M |
| 2022-06-30 | Reported | (m) | $161.00M | (m) | $1.97B | (m) | $52.00M* | $123.00M* | (m) | (m) | $676.00M | $10.00M |
| 2022-03-31 | Reported | (m) | $285.00M | (m) | $1.92B | (m) | $46.00M | -$63.00M | (m) | (m) | $622.00M | -$16.00M |
| 2021-09-30 | Reported | (m) | $574.00M | (m) | $2.11B | (m) | $63.00M* | $564.00M* | (m) | (m) | $653.00M | $25.00M |
| 2021-06-30 | Reported | (m) | -$270.00M | (m) | $2.10B | (m) | $62.00M* | $395.00M* | (m) | (m) | $685.00M | -$77.00M |
| 2021-03-31 | Reported | (m) | -$221.00M | (m) | $2.03B | (m) | $66.00M | $443.00M | (m) | (m) | $606.00M | $16.00M |
| 2020-12-31 | Reported | (m) | -$5.00M | (m) | $2.21B | (m) | (m) | $394.00M | (m) | (m) | (m) | (m) |
| 2020-09-30 | Reported | (m) | $460.00M | (m) | $2.14B | (m) | $81.00M* | $256.00M | (m) | (m) | $572.00M | $5.00M |
| 2020-06-30 | Reported | (m) | -$27.00M | (m) | $1.66B | (m) | $69.00M* | $200.00M | (m) | (m) | $526.00M | -$112.00M |
| 2020-03-31 | Reported | (m) | $248.00M | (m) | $2.01B | (m) | $72.00M | $261.00M | (m) | (m) | $633.00M | -$26.00M |
| 2019-12-31 | Reported | (m) | -$1.08B | (m) | $2.22B | (m) | (m) | $234.00M | (m) | (m) | (m) | (m) |
| 2019-09-30 | Reported | (m) | $329.00M | (m) | $2.21B | (m) | $83.00M* | $515.00M | (m) | (m) | $648.00M | -$18.00M |
| 2019-06-30 | Reported | (m) | $257.00M | (m) | $2.15B | (m) | $62.00M* | $339.00M | (m) | (m) | $651.00M | -$9.00M |
| 2019-03-31 | Reported | (m) | $287.00M | (m) | $2.02B | (m) | $47.00M | $413.00M | (m) | (m) | $587.00M | -$74.00M |
| 2018-12-31 | Reported | (m) | $25.00M | (m) | $2.12B | (m) | (m) | $319.00M | (m) | (m) | (m) | (m) |
| 2018-09-30 | Reported | (m) | $117.00M | (m) | $2.14B | (m) | $32.00M* | $522.00M | (m) | (m) | $614.00M | $51.00M |
| 2018-06-30 | Reported | (m) | -$245.00M | (m) | $2.13B | (m) | $30.00M* | $222.00M | (m) | (m) | $642.00M | $138.00M |
| 2018-03-31 | Reported | (m) | -$2.28B | (m) | $2.00B | (m) | $33.00M | $438.00M | (m) | (m) | $591.00M | -$115.00M |
| 2017-12-31 | Reported | (m) | -$322.00M | (m) | $2.16B | (m) | (m) | $578.00M | (m) | (m) | (m) | (m) |
| 2017-09-30 | Reported | (m) | $38.00M | (m) | $2.22B | (m) | $43.00M* | $490.00M | (m) | (m) | $623.00M | -$1.70B |
| 2017-06-30 | Reported | (m) | $175.00M | (m) | $2.23B | (m) | $37.00M* | $268.00M | (m) | (m) | $659.00M | -$205.00M |
| 2017-03-31 | Reported | (m) | $211.00M | (m) | $2.11B | (m) | $38.00M | $954.00M | (m) | (m) | $661.00M | -$924.00M |
| 2016-12-31 | Reported | (m) | $150.00M | (m) | (m) | (m) | (m) | $512.00M | (m) | (m) | (m) | (m) |
| 2016-09-30 | Reported | (m) | -$863.00M | (m) | (m) | (m) | $53.00M* | $569.00M | (m) | (m) | $661.00M | -$113.00M |
| 2016-06-30 | Reported | (m) | $81.00M | (m) | (m) | (m) | $66.00M* | $449.00M | (m) | (m) | $671.00M | -$73.00M |
| 2016-03-31 | Reported | (m) | $66.00M | (m) | (m) | (m) | $62.00M | $556.00M | (m) | (m) | $813.00M | $7.00M |
| 2015-12-31 | Reported | (m) | $168.00M | (m) | (m) | (m) | (m) | $598.00M | (m) | (m) | (m) | (m) |
| 2015-09-30 | Reported | (m) | $448.00M | (m) | (m) | (m) | $51.10M | $733.00M | (m) | (m) | $697.60M | -$57.40M |
| 2015-06-30 | Reported | (m) | $342.00M | (m) | (m) | (m) | $46.80M | $418.00M | (m) | (m) | $685.50M | -$13.10M |
| 2015-03-31 | Reported | (m) | $569.00M | (m) | (m) | (m) | $65.80M | $509.00M | (m) | (m) | $573.80M | $84.50M |
| 2014-12-31 | Reported | (m) | $617.40M | (m) | (m) | (m) | (m) | $815.70M | (m) | (m) | (m) | (m) |
| 2014-09-30 | Reported | (m) | $671.60M | (m) | (m) | (m) | $39.60M | $618.70M | (m) | (m) | $504.10M | $100.30M |
| 2014-06-30 | Reported | (m) | $355.10M | (m) | (m) | (m) | $113.50M | $376.00M | (m) | (m) | $515.70M | -$1.00M |
| 2014-03-31 | Reported | (m) | $356.60M | (m) | (m) | (m) | $58.10M | $484.30M | (m) | (m) | $482.00M | $25.10M |
| 2013-09-30 | Reported | (m) | -$891.50M | (m) | (m) | (m) | $24.90M | (m) | (m) | (m) | $355.70M | -$169.20M |
| 2013-06-30 | Reported | (m) | $141.50M | (m) | (m) | (m) | $12.80M | (m) | (m) | (m) | $257.30M | -$51.20M |
| 2013-03-31 | Reported | (m) | $117.00M | (m) | (m) | (m) | $14.00M | (m) | (m) | (m) | $241.90M | -$27.30M |
| 2012-09-30 | Reported | (m) | $29.46M | (m) | (m) | (m) | $57.07M | (m) | (m) | (m) | $188.66M | -$96.99M |
| 2012-06-30 | Reported | (m) | $86.81M | (m) | (m) | (m) | $13.60M | (m) | (m) | (m) | $185.44M | $4.55M |
| 2012-03-31 | Reported | (m) | $61.50M | (m) | (m) | (m) | $11.12M | (m) | (m) | (m) | $177.29M | -$260.00K |
| 2011-09-30 | Reported | (m) | $112.36M | (m) | (m) | (m) | $9.58M | (m) | (m) | (m) | $134.80M | -$29.00M |
| 2011-06-30 | Reported | (m) | $118.47M | (m) | (m) | (m) | $12.47M | $226.66M | (m) | (m) | $149.66M | -$12.62M |
| 2011-03-31 | Reported | (m) | $74.74M | (m) | (m) | (m) | $21.50M | $86.33M | (m) | (m) | $139.51M | -$3.37M |
| 2010-09-30 | Reported | (m) | -$126.31M | (m) | (m) | (m) | $1.04M | $110.92M | (m) | (m) | $60.19M | $60.00M |
| 2010-06-30 | Reported | (m) | $48.81M | (m) | (m) | (m) | $2.86M | $108.91M | (m) | (m) | $45.09M | $5.40M |
| 2010-03-31 | Reported | (m) | $16.37M | (m) | (m) | (m) | $3.63M | $44.75M | (m) | (m) | $43.51M | $9.10M |
| 2009-09-30 | Reported | (m) | $58.34M | (m) | (m) | (m) | $1.08M | $89.20M | (m) | (m) | $44.77M | $7.50M |
| 2009-06-30 | Reported | (m) | $10.55M | (m) | (m) | (m) | $842.00K | $97.08M | (m) | (m) | $49.50M | $3.70M |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | $1.81B | (m) | $10.27B | (m) | $397.00M | $1.40B | (m) | (m) | $3.44B | $247.00M |
| 2024-12-31 | Reported | (m) | $1.55B | (m) | $9.63B | (m) | $337.00M | $1.60B | (m) | (m) | $3.30B | $239.00M |
| 2023-12-31 | Reported | (m) | $963.00M | (m) | $8.76B | (m) | $215.00M | $1.03B | (m) | (m) | $2.92B | $221.00M |
| 2022-12-31 | Reported | (m) | $454.00M | (m) | $8.12B | (m) | $218.00M | -$728.00M | (m) | (m) | $2.63B | $83.00M |
| 2021-12-31 | Reported | (m) | $450.00M | (m) | $8.43B | (m) | $269.00M | $1.43B | (m) | (m) | $2.62B | -$87.00M |
| 2021-09-30 | Rolling | (m) | $78.00M* | (m) | $8.45B* | (m) | (m) | $1.80B* | (m) | (m) | (m) | (m) |
| 2021-06-30 | Rolling | (m) | -$36.00M* | (m) | $8.48B* | (m) | (m) | $1.49B* | (m) | (m) | (m) | (m) |
| 2021-03-31 | Rolling | (m) | $207.00M* | (m) | $8.04B* | (m) | (m) | $1.29B* | (m) | (m) | (m) | (m) |
| 2020-12-31 | Reported | (m) | $676.00M | (m) | $8.03B | (m) | $302.00M | $1.11B | (m) | (m) | $2.37B | -$375.00M |
| 2020-12-31 | Rolling | (m) | $676.00M* | (m) | $8.03B* | (m) | (m) | $1.11B* | (m) | (m) | (m) | (m) |
| 2020-09-30 | Rolling | (m) | -$395.00M* | (m) | $8.04B* | (m) | (m) | $951.00M* | (m) | (m) | (m) | (m) |
| 2020-06-30 | Rolling | (m) | -$526.00M* | (m) | $8.11B* | (m) | (m) | $1.21B* | (m) | (m) | (m) | (m) |
| 2020-03-31 | Rolling | (m) | -$242.00M* | (m) | $8.60B* | (m) | (m) | $1.35B* | (m) | (m) | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$203.00M | (m) | $8.60B | (m) | $270.00M | $1.50B | (m) | (m) | $2.55B | -$54.00M |
| 2019-12-31 | Rolling | (m) | -$203.00M* | (m) | $8.60B* | (m) | (m) | $1.50B* | (m) | (m) | (m) | (m) |
| 2019-09-30 | Rolling | (m) | $898.00M* | (m) | $8.50B* | (m) | (m) | $1.59B* | (m) | (m) | (m) | (m) |
| 2019-06-30 | Rolling | (m) | $686.00M* | (m) | $8.43B* | (m) | (m) | $1.59B* | (m) | (m) | (m) | (m) |
| 2019-03-31 | Rolling | (m) | $184.00M* | (m) | $8.40B* | (m) | (m) | $1.48B* | (m) | (m) | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$2.38B | (m) | $8.38B | (m) | $157.00M | $1.50B | (m) | (m) | $2.47B | -$10.00M |
| 2018-12-31 | Rolling | (m) | -$2.38B* | (m) | $8.38B* | (m) | (m) | $1.50B* | (m) | (m) | (m) | (m) |
| 2018-09-30 | Rolling | (m) | -$2.73B* | (m) | $8.42B* | (m) | (m) | $1.76B* | (m) | (m) | (m) | (m) |
| 2018-06-30 | Rolling | (m) | -$2.81B* | (m) | $8.51B* | (m) | (m) | $1.73B* | (m) | (m) | (m) | (m) |
| 2018-03-31 | Rolling | (m) | -$2.39B* | (m) | $8.61B* | (m) | (m) | $1.77B* | (m) | (m) | (m) | (m) |
| 2017-12-31 | Reported | (m) | $102.00M | (m) | $8.72B | (m) | $171.00M | $2.29B | (m) | (m) | $2.58B | -$4.14B |
| 2017-12-31 | Rolling | (m) | $102.00M* | (m) | $8.72B* | (m) | (m) | $2.29B* | (m) | (m) | (m) | (m) |
| 2017-09-30 | Rolling | (m) | $574.00M* | (m) | (m) | (m) | (m) | $2.22B* | (m) | (m) | (m) | (m) |
| 2017-06-30 | Rolling | (m) | -$327.00M* | (m) | (m) | (m) | (m) | $2.30B* | (m) | (m) | (m) | (m) |
| 2017-03-31 | Rolling | (m) | -$421.00M* | (m) | (m) | (m) | (m) | $2.48B* | (m) | (m) | (m) | (m) |
| 2016-12-31 | Reported | (m) | -$566.00M | (m) | $9.67B | (m) | $235.00M | $2.09B | (m) | (m) | $2.81B | -$27.00M |
| 2016-12-31 | Rolling | (m) | -$566.00M* | (m) | (m) | (m) | (m) | $2.09B* | (m) | (m) | (m) | (m) |
| 2016-09-30 | Rolling | (m) | -$548.00M* | (m) | (m) | (m) | (m) | $2.17B* | (m) | (m) | (m) | (m) |
| 2016-06-30 | Rolling | (m) | $763.00M* | (m) | (m) | (m) | (m) | $2.34B* | (m) | (m) | (m) | (m) |
| 2016-03-31 | Rolling | (m) | $1.02B* | (m) | (m) | (m) | (m) | $2.31B* | (m) | (m) | (m) | (m) |
| 2015-12-31 | Reported | (m) | $1.53B | (m) | (m) | (m) | $235.00M | $2.26B | (m) | (m) | $2.70B | $133.00M |
| 2015-12-31 | Rolling | (m) | $1.53B* | (m) | (m) | (m) | (m) | $2.26B* | (m) | (m) | (m) | (m) |
| 2015-09-30 | Rolling | (m) | $1.98B* | (m) | (m) | (m) | (m) | $2.48B* | (m) | (m) | (m) | (m) |
| 2015-06-30 | Rolling | (m) | $2.20B* | (m) | (m) | (m) | (m) | $2.36B* | (m) | (m) | (m) | (m) |
| 2015-03-31 | Rolling | (m) | $2.21B* | (m) | (m) | (m) | (m) | $2.32B* | (m) | (m) | (m) | (m) |
| 2014-12-31 | Reported | (m) | $2.00B | (m) | (m) | (m) | $292.00M | $2.31B | (m) | (m) | $2.03B | $174.00M |
| 2014-12-31 | Rolling | (m) | $2.00B* | (m) | (m) | (m) | (m) | $2.29B* | (m) | (m) | (m) | (m) |
| 2013-12-31 | Reported | (m) | -$409.50M | (m) | (m) | (m) | $115.30M | $1.04B | (m) | (m) | $1.31B | -$450.80M |
| 2012-12-31 | Reported | (m) | $79.70M | (m) | (m) | (m) | $107.60M | $656.60M | (m) | (m) | $756.10M | -$278.20M |
| 2011-12-31 | Reported | (m) | $299.96M | (m) | (m) | (m) | $58.52M | (m) | (m) | (m) | $572.47M | -$177.56M |
| 2010-12-31 | Reported | (m) | -$110.08M | (m) | (m) | (m) | $16.82M | $263.19M | (m) | (m) | $276.55M | -$28.07M |
| 2009-12-31 | Reported | (m) | $181.15M | (m) | (m) | (m) | $7.42M | $360.90M | (m) | (m) | $167.63M | -$1.50M |
| 2008-12-31 | Reported | (m) | $124.11M | (m) | (m) | (m) | $22.00M | $204.32M | (m) | (m) | $188.92M | -$73.00M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |